Beijing Junke Huayuan Pharmaceutical Technology

Beijing Junke Huayuan Pharmaceutical Technology is a Chinese biotechnology company specializing in the development of anti-viral and anti-infective therapeutics. Established in 2005, the company serves as a primary commercialization vehicle for research originating from the Academy of Military Medical Sciences (AMMS). Its most prominent development is JK-05 (favipiravir), a broad-spectrum anti-viral drug that received emergency approval for the treatment of Ebola virus disease. The company focuses on translating military medical innovations into public health solutions, particularly for emergency preparedness and high-threat pathogens. Through strategic licensing agreements, such as with Zhejiang Hisun Pharmaceutical, it facilitates the large-scale production and distribution of its developed compounds.